Zecotek Receives Canadian Patent Allowance For LFS Scintillation Material: related news

Zecotek Receives Canadian Patent Allowance For LFS Scintillation Material

Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I) today announced that the Canadian Patent Office has issued Notice of Allowance to Zecotek Imaging Systems Singapore Pte. Ltd., a wholly-owned subsidiary, for its LFS scintillation material. This application is identical to the LFS scintillation applications that have been issued or allowed in the U.S., Russia, China, Europe and Japan.

Zecotek Receives Canadian Patent Allowance For LFS Scintillation Material

VANCOUVER (Marketwire) - Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I) today announced that the Canadian Patent Office has issued Notice of Allowance to Zecotek Imaging Systems Singapore Pte. Ltd., a wholly-owned subsidiary, for its LFS scintillation material. This application is identical to the LFS scintillation applications that have been issued or allowed in the U.S., Russia, China, Europe and Japan.

Zecotek Receives Canadian Patent Allowance For LFS Scintillation Material

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 29, 2008) - Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I) today announced that the Canadian Patent Office has issued Notice of Allowance to Zecotek Imaging Systems Singapore Pte. Ltd., a wholly-owned subsidiary, for its LFS scintillation material. This application is identical to the LFS scintillation applications that have been issued or allowed in the U.S., Russia, China, Europe and Japan.

Zecotek Receives Canadian Patent Allowance For LFS Scintillation Material

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 29, 2008) - Zecotek Photonics Inc. (TSX VENTURE:ZMS - News; FRANKFURT:W1I - News) today announced that the Canadian Patent Office has issued Notice of Allowance to Zecotek Imaging Systems Singapore Pte. Ltd., a wholly-owned subsidiary, for its LFS scintillation material. This application is identical to the LFS scintillation applications that have been issued or allowed in the U.S., Russia, China, Europe and Japan.

Zecotek gets Canadian patent allowance for LFS material

The Canadian Patent Office has issued a notice of allowance to Zecotek Imaging Systems Singapore Pte. Ltd., a wholly owned subsidiary of Zecotek Photonics Inc., for its LFS scintillation material. This application is identical to the LFS scintillation applications that have been issued or allowed in the United States, Russia, China, Europe and Japan.

Zecotek Receives Canadian Patent Allowance For LFS Scintillation Material

Broadband Service Provider Trident SR Sdn. Bhd.

Zecotek Receives Canadian Patent Allowance for LFS Scintillation Material

Century 21 Real Estate LLC Announces Hispanic Marketing Assessment Program to Debut at Major Hispanic Real Estate Conference

Halliburton Tries To Patent Form Of Patent Trolling

We see all sorts of ridiculous patent applications and patents, but my favorites tend to be the patents that have to do with patents themselves (such as the patent app on a method for filing a patent). However, the folks over at Patently-O have highlighted a fascinating patent application from an attorney at Halliburton, which appears to be an attempt to patent the process of patent trolling. The application covers, quite explicitly, having a company (we'll say Company A) that does not invent something, find a company (Company B) that did invent something, but chose to use trade secret protection, rather than patents. Then, the Company A files a patent covering Company B's technology, and then use the issued patent to get money out of Company B.

Halliburton Applies For Patent-Trolling Patent

An anonymous reader writes "Halliburton, the company many folks know as Dick Cheney's previous employer, has apparently taken an interest in methods of patent trolling. In fact, according to Techdirt, the company has applied for a patent on patent trolling. Specifically, it's applied for a patent on the process of finding a company that protected an invention via trade secret, figuring out what that secret is, patenting it ... and then suing the original company. Hopefully, the patent office rejects this patent, because I somehow doubt that Halliburton is trying to get the patent as a way to block others from patent trolling."

i2Telecom Receives Notice of Allowance from U.S. Patent and Trademark Office for "Dynamic Transmission of Packets Over Broadband" Patent

TMCNet: i2Telecom Receives Notice of Allowance from U.S. Patent and Trademark Office for "Dynamic Transmission of Packets Over Broadband" Patent

Patent Lawsuit Silly Season: TechCrunch Sued For Patent Infringement After Critical Blog Post

There are different levels of ridiculousness when it comes to patent lawsuits, with the lowest of the low being patent lawsuits based more on spite than on any legitimate claim. For a while, it seemed like Ray Niro's use of the infamous JPG patent, to sue a bunch companies he just didn't like, was perhaps alone in that category. But, it appears that we now have a new entrant. Apparently, some company (who we won't even name, since there's a good chance it's doing this just to get press attention) sued a more well-known competitor for patent infringement, over a location-based services patent. Looking over the patent itself it's difficult to see how it was approved. People were talking about location-based profile matching a decade ago, let alone five years ago when this patent was filed.

i2Telecom Receives Notice of Allowance from U.S. Patent and Trademark Office for "Dynamic Transmission of Packets Over Broadband" Patent

Patent Covers Technology Utilized by OEMs and Communication Services Providers; Company Believes Patent Substantially Exceeds Value of VoiceStick(R) Patent Previously Sold for $6.5 Million

i2Telecom Receives Notice of Allowance from U.S. Patent and Trademark Office for "Dynamic Transmission of Packets Over Broadband" Patent

Patent Covers Technology Utilized by OEMs and Communication Services Providers; Company Believes Patent Substantially Exceeds Value of VoiceStick(R) Patent Previously Sold for $6.5 Million

Ameranth Receives Major Patent for Its 'Casino Poker and Dealer Management System'

SAN DIEGO, Oct. 15 /PRNewswire/ -- Ameranth, Inc. announced today that it has received an official patent grant (#7,431,650) from the United States Patent and Trademark Office for a major patent, which will have a term extending to December 2025, on its revolutionary, automated poker and dealer system invention. The patent is the result of work dating from 2001. The award of this key strategic patent confirms Ameranth's leading and pioneering role in automating the modern poker room and clearly establishes Ameranth as a technology leader in virtually all automated aspects of poker rooms as part of Ameranth's overall 21st Century Casino(TM) vision. This new patent, combined with Ameranth's portfolio of wireless/web data synchronization patents (applicable to wireless gaming and many other casino applications) and Ameranth's recent and plan

Key Fondaparinux Patent Allowed by U.S. Patent Office

Australian drug developer Alchemia Limited (ASX:ACL) today announced it had received a 'notice of allowance' for the United States patent application titled Synthetic Heparin Pentasaccharides (number 10/488,677). A notice of allowance is a notification to the patent applicant that they are entitled to a patent under the law and is issued for applications that have been filed based on "intent to use." The patent number will be assigned on payment of the grant fees.

Key Fondaparinux Patent Allowed by U.S. Patent Office

2008 NOV 7 - (NewsRx.com) -- Australian drug developer Alchemia Limited (ASX:ACL) announced it had received a 'notice of allowance' for the United States patent application titled Synthetic Heparin Pentasaccharides (number 10/488,677). A notice of allowance is a notification to the patent applicant that they are entitled to a patent under the law and is issued for applications that have been filed based on "intent to use." The patent number will be assigned on payment of the grant fees (see also Alchemia Limited).

Key Fondaparinux Patent Allowed by U.S. Patent Office

BRISBANE, Australia--(BUSINESS WIRE)--Oct 21, 2008 - Australian drug developer Alchemia Limited (ASX:ACL) today announced it had received a 'notice of allowance' for the United States patent application titled Synthetic Heparin Pentasaccharides (number 10/488,677). A notice of allowance is a notification to the patent applicant that they are entitled to a patent under the law and is issued for applications that have been filed based on "intent to use." The patent number will be assigned on payment of the grant fees.

Hit By Poor Economy? MobileRobots Inc Wants to Help You Become A Robot Solution Provider

AutoServiceWorld.com Bodyshop Broadcaster Building Canadian Interiors Cabling Networking Systems Canadian Architect Canadian Industrial Equipment News Canadian Underwriter Canadian Consulting Engineer Canadian Plastics Canadian Mining Journal Canadian Oil Register Canadian Transportation & Logistics Centre EcoLog EcoLog Eris

Biodel receives notice of allowance for insulin patent claims in Europe

Biodel Inc announced that it has received a notice of allowance from the European Patent Office for patent claims covering compositions and uses of formulations of insulin for Biodel's two lead product candidates, VIAject and VIAtab, in the treatment of diabetes. After their publication and once they are issued, the patent claims will have a term of 20 years from the international filing date of March 11, 2005.

Biodel Receives Notice of Allowance for Insulin Patent Claims in Europe

Biodel Inc. (BIOD) announced today that it has received a notice of allowance from the European Patent Office for patent claims covering compositions and uses of formulations of insulin for Biodel's two lead product candidates, VIAject(TM) and VIAtab(TM), in the treatment of diabetes. After their publication and once they are issued, the patent claims will have a term of 20 years from the international filing date of March 11, 2005.

Biodel Receives Notice of Allowance for Insulin Patent Claims in Europe

Biodel Inc. (Nasdaq: BIOD) announced today that it has received a notice of allowance from the European Patent Office for patent claims covering compositions and uses of formulations of insulin for Biodel's two lead product candidates, VIAject(TM) and VIAtab(TM), in the treatment of diabetes. After their publication and once they are issued, the patent claims will have a term of 20 years from the international filing date of March 11, 2005.

Biodel Receives Notice of Allowance for Insulin Patent Claims in Europe

DANBURY, Conn.-- (BUSINESS WIRE) -- Biodel Inc. (Nasdaq: BIOD) announced today that it has received a notice of allowance from the European Patent Office for patent claims covering compositions and uses of formulations of insulin for Biodel's two lead product candidates, VIAject(TM) and VIAtab(TM), in the treatment of diabetes. After their publication and once they are issued, the patent claims will have a term of 20 years from the international filing date of March 11, 2005.

Biodel Receives Notice of Allowance for Insulin Patent Claims in Europe

DANBURY, Conn. - (Business Wire) Biodel Inc. (Nasdaq: BIOD) announced today that it has received a notice of allowance from the European Patent Office for patent claims covering compositions and uses of formulations of insulin for Biodel's two lead product candidates, VIAject(TM) and VIAtab(TM), in the treatment of diabetes. After their publication and once they are issued, the patent claims will have a term of 20 years from the international filing date of March 11, 2005.

Biodel Receives Notice of Allowance for Insulin Patent Claims in Europe

DANBURY, Conn.--(BUSINESS WIRE)--Oct 13, 2008 - Biodel Inc. (Nasdaq: BIOD) announced today that it has received a notice of allowance from the European Patent Office for patent claims covering compositions and uses of formulations of insulin for Biodel's two lead product candidates, VIAject(TM) and VIAtab(TM), in the treatment of diabetes. After their publication and once they are issued, the patent claims will have a term of 20 years from the international filing date of March 11, 2005.

::: Biodel Receives Notice of Allowance for Insulin Patent Claims in Europe

DANBURY, Conn.--(BUSINESS WIRE)--Biodel Inc. (Nasdaq: BIOD) announced today that it has received a notice of allowance from the European Patent Office for patent claims covering compositions and uses of formulations of insulin for Biodel's two lead product candidates, VIAject(TM) and VIAtab(TM), in the treatment of diabetes. After their publication and once they are issued, the patent claims will have a term of 20 years from the international filing date of March 11, 2005.

Search took 0.28 seconds.